IP Library Granted Patent US 12,661,404
Granted Patent B2
US 12,661,404 · App. 18/021,249 · Granted Jun 23, 2026

Methods and materials for tissue ablation

Inventors: Rahmi Oklu (Chandler, AZ); Hassan Albadawi (Tempe, AZ); Samir Mitragotri (Lexington, MA)
Assignees: Mayo Foundation for Medical Education and Research; President and Fellows of Harvard College
A61K41/0052A61K9/0019A61K9/0024A61K31/201A61K31/704A61K47/02A61K49/0034A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,661,404
App. No.
18/021,249
Granted
Jun 23, 2026
Kind
B2
Abstract

This document relates to methods and materials for tissue ablation. For example, methods for using a composition including one or more ionic liquids (e.g., a composition including a LATTE solution) for tissue ablation are provided. In some cases, a composition including one or more ionic liquids (e.g., a composition including a LATTE solution) can be used to ablate tumor tissue within a mammal having cancer (e.g., to treat the mammal).

Claims (35)

1 . A method for ablating at least a portion of a tissue within a mammal, wherein said method comprises percutaneously injecting a composition comprising an ionic liquid into said tissue within said mammal,

wherein said ionic liquid comprises:

(a) a cationic component comprising choline; and

(b) an anionic component comprising geranate;

wherein the composition does not comprise any additional therapeutic agent,

wherein the choline and geranate are in a ratio of 1:1,

wherein said composition is in the form of an aqueous solution or a hydrogel comprising a nanosilicate and is effective to create an ablation zone within said tissue,

wherein when the composition is aqueous, the composition comprises 10-90% (w/w) of the choline geranate, and wherein said composition is effective to reduce the number of cells within said ablation zone.

2 . The method of claim 1 , wherein said mammal is a human.

3 . The method of claim 1 , wherein said tissue is selected from the group consisting of fat tissue, cardiac tissue, connective tissue, bone tissue, synovial tissue, abscess tissue, and cysts.

4 . The method of claim 3 , wherein said percutaneously injecting step comprises a guided injection.

5 . The method of claim 4 , wherein said composition comprising an ionic liquid further comprises a contrast agent.

6 . The method of claim 5 , wherein said contrast agent is selected from the group consisting of indocyanine green, a radiodense contrast agent, iohexol, tantalum nanoparticles, tantalum microparticles, gold nanoparticles, gadolinium, indium 111 , and microbubbles.

7 . The method of claim 1 , wherein said ablation zone is from about 0.1 cm to about 4 cm.

8 . A method for treating a mammal having cancer, wherein said method comprises percutaneously injecting a composition comprising an ionic liquid into a tumor tissue within said mammal,

wherein said ionic liquid comprises:

(a) a cationic component comprising choline; and

(b) an anionic component comprising geranate;

wherein the composition does not comprise any additional therapeutic agent,

wherein the choline and geranate are in a ratio of 1:1,

wherein said composition is in the form of an aqueous solution or a hydrogel comprising a nanosilicate and is effective to create an ablation zone within said tumor tissue,

wherein when the composition is aqueous, the composition comprises 10-90% (w/w) of the choline geranate, and

wherein said composition is effective to reduce the number of cancer cells within said ablation zone.

9 . The method of claim 8 , wherein said mammal is a human.

10 . The method of claim 8 , wherein said cancer is selected from the group consisting of a liver cancer, a bile duct cancer, a pancreatic cancer, a colorectal cancer, a renal cancer, an ovarian cancer, a breast cancer, a prostate cancer, a colon cancer, a bladder cancer, a lung cancer, a thyroid cancer, a melanoma, a brain cancer, a stomach cancer, a cervical cancer, a uterine cancer, a skin cancer, a synovial cancer, an appendiceal cancer, and an adrenal cancer.

11 . The method of claim 8 , wherein said percutaneously injecting step comprises a guided injection, and wherein said composition comprises a contrast agent.

12 . The method of claim 11 , wherein said contrast agent is selected from the group consisting indocvanine green, a radiodense contrast agent, iohexol, tantalum nanoparticles, tantalum microparticles, gold nanoparticles, gadolinium, indium 111 , and microbubbles.

13 . The method of claim 11 , wherein said ionic liquid choline geranate.

14 . The method of claim 11 , wherein said method is effective to maintain said ionic liquid within said ablation zone for from about 1 day to about 30 days.

15 . The method of claim 8 , wherein said method is effective to reduce the size of said cancer by at least 2-fold.

16 . The method of claim 8 , said method comprising identifying said mammal as having said cancer.

17 . The method of claim 1 , wherein said composition is in the form of a hydrogel.

18 . The method of claim 17 , wherein said hydrogel comprises from about 1% (w/v) to about 10% (w/v) of said nanosilicate.

19 . The method of claim 18 , wherein said nanosilicate comprises a smectite clay.

20 . The method of claim 1 , wherein said composition is in the form of an aqueous solution.